Literature DB >> 17872396

Morphogen receptor genes and metamorphogenes: skeleton keys to metamorphosis.

Frederick S Kaplan1, Jay Groppe, Robert J Pignolo, Eileen M Shore.   

Abstract

Morphogen receptors are nodal points in signal transduction pathways that regulate morphogenesis during embryonic development. A recent discovery identified a recurrent missense mutation in a gene encoding a morphogen receptor responsible for the elusive process of skeletal metamorphosis in humans. Metamorphosis, the postnatal transformation of one normal tissue or organ system into another, is a biological process rarely seen in higher vertebrates or mammals, but exemplified pathologically by the disabling autosomal dominant disorder, fibrodysplasia ossificans progressiva (FOP). Individuals with FOP experience episodes of spontaneous or trauma-induced metamorphosis that convert normal functioning aponeuroses, fascia, ligaments, tendons, and skeletal muscles into a highly ramified and disabling second skeleton of heterotopic bone. The recurrent single nucleotide missense mutation in the gene encoding activin receptor IA/activin-like kinase 2 (ACVR1/ALK2), a bone morphogenetic protein (BMP) type I receptor that causes FOP in all classically affected individuals worldwide, is one of the most specific disease-causing mutations in the human genome and the first identified human metamorphogene. These findings provide deep insight into a signaling pathway that regulates tissue and organ stability following morphogenesis, and that when dysregulated in a specific manner, orchestrates the metamorphosis of one normal tissue or organ system into another. The study of skeletal metamorphosis in FOP provides profound insight into the molecular mechanisms that ensure phenotypic stability following morphogenesis and that ordinarily lay deeply hidden in the highly conserved signaling pathways that regulate cell fate. Such insight is applicable to a broad range of human afflictions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17872396     DOI: 10.1196/annals.1402.039

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  23 in total

1.  Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Petra Seemann; Julia Haupt; Meiqi Xu; Vitali Y Lounev; Mary Mullins; Eileen M Shore
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

2.  Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.

Authors:  Kyosuke Hino; Kazuhiko Horigome; Megumi Nishio; Shingo Komura; Sanae Nagata; Chengzhu Zhao; Yonghui Jin; Koichi Kawakami; Yasuhiro Yamada; Akira Ohta; Junya Toguchida; Makoto Ikeya
Journal:  J Clin Invest       Date:  2017-07-31       Impact factor: 14.808

3.  Fibrodysplasia ossificans progressiva (FOP): watch the great toes!

Authors:  Mutlu Kartal-Kaess; Eileen M Shore; Meiqi Xu; Ludwig Schwering; Markus Uhl; Rudolf Korinthenberg; Charlotte Niemeyer; Frederick S Kaplan; Melchior Lauten
Journal:  Eur J Pediatr       Date:  2010-06-26       Impact factor: 3.183

Review 4.  Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation.

Authors:  Irina Hüning; Gabriele Gillessen-Kaesbach
Journal:  Mol Syndromol       Date:  2014-08-07

5.  Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.

Authors:  Kyosuke Hino; Makoto Ikeya; Kazuhiko Horigome; Yoshihisa Matsumoto; Hayao Ebise; Megumi Nishio; Kazuya Sekiguchi; Mitsuaki Shibata; Sanae Nagata; Shuichi Matsuda; Junya Toguchida
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

Review 6.  Cellular and morphological aspects of fibrodysplasia ossificans progressiva. Lessons of formation, repair, and bone bioengineering.

Authors:  Anderson Martelli; Arnaldo Rodrigues Santos
Journal:  Organogenesis       Date:  2014-10-31       Impact factor: 2.500

7.  Pregnancy in fibrodysplasia ossificans progressiva.

Authors:  Javaid A Muglu; Aditya Garg; T Pandiarajan; Eileen M Shore; Frederick S Kaplan; Dhiraj Uchil; Malcolm J Dickson
Journal:  Obstet Med       Date:  2011-12-08

8.  When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).

Authors:  Frederick S Kaplan; Jay Groppe; Eileen M Shore
Journal:  Drug Discov Today Ther Strateg       Date:  2008

9.  Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.

Authors:  Frederick S Kaplan; Meiqi Xu; Petra Seemann; J Michael Connor; David L Glaser; Liam Carroll; Patricia Delai; Elisabeth Fastnacht-Urban; Stephen J Forman; Gabriele Gillessen-Kaesbach; Julie Hoover-Fong; Bernhard Köster; Richard M Pauli; William Reardon; Syed-Adeel Zaidi; Michael Zasloff; Rolf Morhart; Stefan Mundlos; Jay Groppe; Eileen M Shore
Journal:  Hum Mutat       Date:  2009-03       Impact factor: 4.878

Review 10.  The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling.

Authors:  Frederick S Kaplan; Robert J Pignolo; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2009-11-06       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.